secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alpha Teknova, Inc. (TKNO)
CIK:        0001850902
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0000950170-23-041316
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Teknova Q2 revenue $11.5M (+26% seq, -1% YoY); cuts 2023 revenue guidance to $37-40M
--------------------------------------------------------------------------------

- Q2 revenue $11.5M, up 26% sequentially but down 1% YoY; net loss $7.2M ($0.25/share).
- Clinical Solutions revenue grew 24% YoY to $3.7M; Lab Essentials fell 10% to $7.6M.
- Company reduces 2023 revenue guidance to $37-40M from prior; maintains free cash outflow ~$30M.
- Received certification for new GMP production facility, expanding capacity to $200M.
- Adjusted EBITDA improved to -$2.3M from -$4.9M; non-cash impairment charge of $2.2M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850902/000095017023041316/0000950170-23-041316-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850902/000095017023041316/tkno-20230810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-041316

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer